Sacubitril/Valsartan Versus Valsartan Initiation in Patients Naïve to Renin–angiotensin System Inhibitors: Insights from PARAGLIDE-HF
In HF with EF >40% stabilized after worsening HF, safety and efficacy were similar irrespective of ACEi/ARB status at baseline, supporting early initiation irrespective of prior ACEi/ARB use.
Authors
- Serge Lepage (ORCID: https://orcid.org/0000-0002-4242-9740)
- Adrian F. Hernandez (ORCID: https://orcid.org/0000-0003-3387-9616)
- Nina Nouhravesh (ORCID: https://orcid.org/0000-0002-4891-7358)
- Eric J. Velazquez (ORCID: https://orcid.org/0000-0003-2245-7477)
- Kristin Williamson (ORCID: https://orcid.org/0000-0003-2131-0481)
- Randall C. Starling (ORCID: https://orcid.org/0000-0002-1254-4860)
- Kavita Sharma (ORCID: https://orcid.org/0000-0002-3012-1765)
- David A. Morrow (ORCID: https://orcid.org/0000-0002-9589-5382)
- Alexander Gunn (ORCID: https://orcid.org/0000-0001-8912-4867)
- Robert John Mentz (ORCID: https://orcid.org/0000-0002-3222-1719)
- Derek D. Cyr (ORCID: https://orcid.org/0000-0001-6545-9240)
- Jonathan H. Ward (ORCID: https://orcid.org/0009-0002-6739-6567)
- Shelley R. Zieroth (ORCID: https://orcid.org/0000-0002-6145-9814)
- Scott Solomon
- Samiha Sarwat
Institutions
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- Université de Sherbrooke (CA)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Gentofte Hospital (DK)
- Yale University (US)
- Clinical Research Institute (US)
- Novartis (United States) (US)
- Tris Pharma (United States) (US)
- University of Manitoba (CA)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1002/ejhf.3579
- Citations
- 5
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.94
Funders
- Novartis Pharmaceuticals Corporation